Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.

ABSTRACT:

Background and objectives

Biomarkers may improve identification of individuals at risk of eGFR decline who may benefit from intervention or dialysis planning. However, available biomarkers remain incompletely validated for risk stratification and prediction modeling.

Design, setting, participants, & measurements

We examined serum cystatin C, urinary kidney injury molecule-1 (uKIM-1), and urinary neutrophil gelatinase-associated lipocalin (UNGAL) in 5367 individuals with type 2 diabetes mellitus and recent acute coronary syndromes enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial. Baseline concentrations and 6-month changes in biomarkers were also evaluated. Cox proportional regression was used to assess association

SUBMITTER: Garlo KG 

PROVIDER: S-EPMC5967667 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature